← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 17.0% to $64.0M, while Net income increased 46.3% to $7.5M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $64.0MOK
- Profitability — Net income $7.5MOK
- Cash generation — Free cash flow $11.1MOK
- Accounting — Distress-safe · no manipulation flag · earnings quality safeOK
- Insiders — 0 buys; 2 sells in 365 daysNote
- Capital — share repurchases were $10.0MNote
Business
Electromed, Inc.: ("we," "our," "us," "Electromed" or the "Company") develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest ® Airway Clearance System ("SmartVest System") to patients with compromised pulmonary function with a commitment to excellence and compassionate service.
Where the revenue comes from
Fiscal 2025, as Electromed, Inc. reports it. History and quarterly detail are in the app.
- Third Party Payer Commercial$29.1M
- Third Party Payer Medicare$21.0M
- Third Party Payer Medicare Supplemental$5.2M
- Thirdparty Other$1.1M
- Third Party Payer Medicaid$922K
Leadership changes
From Electromed, Inc.'s own filings, the day they're filed.
- James L. Cunniff · Chief Executive Officer · appointment
Latest filings
- 8-K · Company announcement2026-08-25
- 10-K · Annual report2026-08-25
- 8-K · Company announcement2026-05-12
- 10-Q · Quarterly report2026-05-12
- 10-Q · Quarterly report2026-02-10
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Electromed, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.